Skip to main content

Table 2 Overview prevalence of SMA by subtype

From: Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review

Country

Time point

SMA

Type I

Quality and comparability

Reference

  

No of patients

Population

per 100,000

No of patients

Population

per 100,000

 

 Norway (Southern + Eastern)

01/01/1983

24

573,762

4.18

1

573,762

0.17

Only included patients below 18 years of age

Tangsrud_1988 [25]

 Sweden (Western)

31/12/2006

11

340,179

3.23

-

-

-

Genetic diagnosis used

Only included patients below 16 years of age

Arkblad_2009 [23]

 Sweden (Western)

01/01/1995

10

359,676

2.78

1

359,676

0.28

Only included patients below 16 years of age

Darin_2000 [24]

 Estonia

31/12/2003

-

-

-

2

1,351,069

0.15

Genetic diagnosis used

Vaidla_2006 [34]

 United Kingdom (Northern Ireland)

30/06/1994

22

1,573,282

1.40

-

-

-

 

Hughes_1996 [110]

 United Kingdom (Northern England)

01/08/2007

56

2,991,517

1.87

3

2,991,517

0.10

Genetic diagnosis used in most cases

Norwood_2009 [32]

 Germany (West‑Thüringen)

31/12/1987

-

-

-

3

1,778,200

0.17

 

Thieme_1993 [33]

 Italy (Bologna)

31/12/1989

10

152,529

6.56

-

-

-

Only included patients below 20 years of age

Merlini_1992 [22]

 Saudi Arabia (Northeast, Thugbah)

02/08/1989

3

22,630

13.26

1

22,630

4.42

In half of the cases parental consanguinity was observed

al Rajeh_1993 [29]

 China (Hongkong)

30/06/2001

25

1,335,469

1.87

2

1,335,469

0.15

Partly used genetic diagnosis

Chung_2003 [31]

 Canada (Toronto)

1962–1964

20.33

2,748,500

0.74

-

-

-

Average of a three-year period

Winsor_1971 [111]

Country

Time point

Type II

Type III

Type II + III

Quality and comparability

Reference

  

No of patients

Population

per 100,000

No of patients

Population

per 100,000

No of patients

Population

per 100,000

  

 Norway (Southern + Eastern)

01/01/1983

21

573,762

3.66

2

573,762

0.35

23

573,762

4.01

Only included patients below 18 years of age

Tangsrud_1988 [25]

 Sweden (Western)

01/01/1995

4

359,676

1.11

5

359,676

1.39

9

359,676

2.50

Only included patients below 16 years of age

Darin_2000 [24]

 United Kingdom (Northern England)

01/08/2007

17

2,991,517

0.57

36

2,991,517

1.20

53

2,991,517

1.77

Genetic diagnosis used in most casesa

Norwood_2009 [32]

 United Kingdom (Northeast England)

June 1971

-

-

-

-

-

-

30

2,488,810

1.21

Type II/III patients defined as: onset of disease between birth and 8 years of age, survival above 18 months of age

Pearn_1978 [41]

 Germany (West‑Thüringen)

31/12/1980

-

-

-

-

-

-

29

1,785,239

1.62

Type II/III patients defined as: survival above 4 years of age

Exact number of patients not mentionedb

Thieme_1994 [43]

 Poland (Warsaw)

31/12/1985

-

-

-

-

-

-

21

1,659,385

1.26

Exact number of patients not mentionedb

Spiegler_1990 [42]

 Libya (Benghazi)

31/12/1986

-

-

-

-

-

-

12

-

2.30

In half of the cases parental consanguinity was observed

Radhakrishan_1988 [48]

 Saudi Arabia (Northeast, Thugbah)

02/08/1989

2

22,630

8.84

-

-

-

-

-

-

In half of the cases parental consanguinity was observed

al Rajeh_1993 [29]

 China (Hongkong)

30/06/2001

9

1,335,469

0.67

14

1,335,469

1.05

23

1,335,469

1.72

Partly used genetic diagnosis

Chung_2003 [31]

  1. Prevalence per 100,000 persons of the total population. Studies have been grouped by geographical region. Studies are based on clinical diagnosis, unless otherwise indicated. Indicated if described in article that different classification criteria than those in Table 1 were used
  2. a) 17 patients are classified as type III on clinical and neurophysiological findings in the absence of a confirmed mutation in the SMN1 gene
  3. b) Number of patients not described in article, calculated based on prevalence and population number